Renutend contains primed mesenchymal stem cells (MSCs) which Boehringer says are specifically targeted to reduce scar tissue formation so horses can return to the intended level of performance, with a reduced risk of re-injury1.
According to the company, a single dose decreases scar tissue formation with consistent and proven results 2.
RenuTend is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell Forte, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
RenuTend will be available in September this year.
In the meantime, Boehringer is encouraging veterinary surgeons to register their interest with their BIAH representative or call 01344746960 in order to get updates or product information as soon as it becomes available.
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.
Publishing Editor: Arlo Guthrie
Clinical Editor: Alasdair Hotston Moore MA VetMB CertSAC CertVR CertSAS FRCVS
Facebook | Linkedin | Instagram | Twitter
Learn more about advertising on VetSurgeon.org
VetSurgeon Jobs is the place to advertise and find permanent and locum jobs for veterinary surgeons in England | Scotland | Wales | Ireland and Worldwide. Follow VS Jobs on Facebook | Linkedin | Twitter
Veterinary Anaesthesia | Veterinary Cardiology | Veterinary Dentistry | Veterinary Dermatology | Diagnostic Imaging | Veterinary ECC | Equine Medicine & Surgery | Farm Animal Medicine & Surgery | Veterinary Medicine | Veterinary Neurology Veterinary Oncology | Veterinary Ophthalmology | Veterinary Orthopaedics | Pathology/Cytology | Veterinary Surgery